Finance

Lists
532488:BOM
Divi's Laboratories Ltd
₹9 039,95
+0,11%
(+10,10) 1D
15 Okt., 15:54:14 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 532488...
Open
₹9 066,00
High
₹9 123,80
Low
₹8 949,10
Mkt. cap
2,41 bn
Avg. vol.
37,11 k
Volume
44,26 k
Dividend
0,33%
Quarterly dividend
₹7,50
Ex-dividend date
24 Jul. 2026
P/E ratio
82,04
52-wk high
₹10 000,00
52-wk low
₹5 648,00
EPS
₹110,20
Shares outstanding
265,47 m
No. of employees
12 k
Open
₹9 066,00
High
₹9 123,80
Low
₹8 949,10
Mkt. cap
2,41 bn
Avg. vol.
37,11 k
Volume
44,26 k
Dividend
0,33%
Quarterly dividend
₹7,50
Ex-dividend date
24 Jul. 2026
P/E ratio
82,04
52-wk high
₹10 000,00
52-wk low
₹5 648,00
EPS
₹110,20
Shares outstanding
265,47 m
No. of employees
12 k
News stories
From web sources and news partners
Profile
Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients and intermediates, headquartered in Hyderabad. The company manufactures and custom synthesizes generic APIs, intermediates. The company also manufactures and supplies nutraceutical ingredients through its subsidiary, Divi's Nutraceuticals. Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization. Wikipedia
About Divi's Laboratories Ltd
CEOKiran S. Divi
Employees11,6 k
Founded12 Okt. 1990
Headquarters-
SectorHealth care
Last report
01 Aug. 2026
Fiscal period
Q1 2027
₹33,95 / ₹24,68
+37,58%beat
Revenue / Est. (INR)
30,80 mjd / 27,61 mjd
+11,56%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
27,15 mjd
26,04 mjd
28,31 mjd
30,80 mjd
Cost of goods sold
10,73 mjd
9,45 mjd
13,49 mjd
9,86 mjd
Cost of revenue
10,73 mjd
9,45 mjd
13,49 mjd
9,86 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,54 mjd
3,67 mjd
3,99 mjd
4,08 mjd
Operating expense
8,67 mjd
8,87 mjd
6,68 mjd
9,65 mjd
Total operating expenses
19,40 mjd
18,32 mjd
20,17 mjd
19,51 mjd
Operating income
7,75 mjd
7,72 mjd
8,14 mjd
11,29 mjd
Other non operating income
820,00 m
690,00 m
-2,23 mjd
640,00 m
EBT including unusual items
9,12 mjd
7,80 mjd
9,63 mjd
11,80 mjd
EBT excluding unusual items
9,12 mjd
8,54 mjd
9,59 mjd
11,80 mjd
Income tax expense
2,23 mjd
1,97 mjd
2,12 mjd
2,78 mjd
Effective tax rate
24,45%
25,26%
22,01%
23,56%
Other operating expenses
4,00 mjd
4,02 mjd
1,49 mjd
4,24 mjd
Net income
6,89 mjd
5,83 mjd
7,51 mjd
9,02 mjd
Net profit margin
25,38%
22,39%
26,53%
29,29%
Earnings per share
25,97
24,07
28,31
33,95
Interest and investment income
-
-
2,84 mjd
-
Interest expense
-80,00 m
-60,00 m
-60,00 m
-60,00 m
Net interest expenses
-80,00 m
-60,00 m
2,78 mjd
-60,00 m
Depreciation and amortization charges
1,13 mjd
1,18 mjd
1,20 mjd
1,33 mjd
EBITDA
8,88 mjd
8,72 mjd
9,29 mjd
12,44 mjd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme